Evidence mapPaperPMID 42539696Full record

ReviewFrontiers in pediatrics2026

MSCs and MSC-Exos in pediatric ARDS treatment: translational research and the reshaping of nursing roles.

Li Zhang, Lingli Jian

Abstract readReview
In one paragraph

Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Li ZhangDepartment of Pediatrics, Daping Hospital, Army Medical University, Chongqing, China.
Lingli JianDepartment of Pediatrics, Daping Hospital, Army Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition with high mortality and limited conventional treatments. Mesenchymal stem cells (MSCs), which are special cells that can develop into a variety of cell types, and their tiny vesicles called exosomes (MSC-Exos), are highly promising cell-based therapies for pediatric ARDS because of their anti-inflammatory, immunomodulatory, and tissue-repair functions. This review summarizes current knowledge on MSCs and MSC-Exos in ARDS, including recent progress in studies before human trials and in actual patient trials. It focuses on challenges, needed competency changes, and how nursing roles are evolving in this new therapeutic field. The discussion provides a theoretical foundation for developing a nursing framework to support and enhance patient care with advanced cell therapies.

Indexed as

MSC-Exos nursing roleMSCspediatric ARDStranslational medicine

Identifiers

PMID42539696
PMCPMC13424481

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.